Baicalein Acts against Candida albicans by Targeting Eno1 and Inhibiting Glycolysis-Reference-Cited by-同舟云学术

Baicalein Acts against Candida albicans by Targeting Eno1 and Inhibiting Glycolysis

Published:2022-08-31 Issue:4 Volume:10 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Li Liping¹,Lu Hui¹^ORCID,Zhang Xuan²,Whiteway Malcolm³,Wu Hao¹,Tan Shanlun⁴,Zang Jianye²,Tian Shujuan⁴,Zhen Cheng¹,Meng Xianlei²,Li Wanqian¹,Zhang Dazhi¹⁴,Zhang Min²,Jiang Yuanying¹

Affiliation:

1. Department of Pharmacy, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China

2. Hefei National Laboratory for Physical Sciences at Microscale, the First Affiliated Hospital of USTC, CAS Center for Excellence in Biomacromolecules, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui, China

3. Department of Biology, Concordia University, Montreal, Quebec, Canada

4. Department of Organic Chemistry, School of Pharmacy, Naval Medical University, Shanghai, China

Abstract

Baicalein (BE) is a promising antifungal agent which has been well characterized, but its target protein is still undiscovered. The protein Eno1 plays a crucial role in the survival of Candida albicans .

Funder

National Natural Science Foundation of China

MOST | National Key Research and Development Program of China

Innovation Program of Shanghai Municipal Education Commission

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.02085-22

Reference63 articles.

1. Breakthrough invasive fungal infections: Who is at risk?